Siliq provides option for patients with prior psoriasis treatment failures
Click Here to Manage Email Alerts
Treatment with Siliq may lead to long-term skin clearance among patients with psoriasis who require an option following prior therapeutic avenues, according to a study published in the Journal of Drugs in Dermatology.
“Although biologic therapies have significantly advanced psoriasis treatments, many unmet needs remain,” Mark G. Lebwohl, MD, of the Icahn School of Medicine at Mount Sinai, and colleagues wrote. “Long-term treatment is required in up to 90% of cases because of the relapsing-remitting nature of the disease.”
Siliq (brodalumab, Amgen), a human interleukin-17 (IL-17) receptor A antagonist, was approved by the FDA in 2017 for the treatment of moderate to severe psoriasis among adults who failed to respond or lost response to other systemic therapies.
Lebwohl and colleagues reviewed published data on outcomes of treatment with brodalumab.
They found that brodalumab improved plaque psoriasis lesions after attempts with other IL-17 inhibitors, has long-term effectiveness after treatment failure with TNF-alpha inhibitors, produces treatment response in patients previously treated with IL-12 or IL-23 inhibitors, and induces long-term treatment response after treatment failure with multiple biologics.
“Patients with prior biologic failure or loss of response are a subset of individuals with psoriasis who most likely have a more severe disease with a greater impact on quality of life,” Lebwohl and colleagues wrote. “It is important to determine therapeutic approaches that will help these patients long-term, as psoriasis can have multifaceted physical effects and psychological consequences.”
Additionally, the researchers noted that switching between multiple biologics is associated with clinical consequences that may limit the efficacy of subsequent biologic therapies.
“Many factors should be considered when selecting the optimal therapy for a patient with psoriasis,” the researchers wrote. “Given the evidence, brodalumab is a viable treatment for patients who have failed or lost efficacy to a single prior biologic, while also offering long-term skin clearance for patients with a history of multiple biologic drug failures.”